[A22-133] Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V

Last updated 15.06.2023

Project no.:
A22-133

Commission:
Commission awarded on 21.12.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Digestion, metabolism and hormones

Indication:

Adults with moderately to severely active Crohn’s disease

Result of dossier assessment:
  • who have had an inadequate response to, lost response to, or were intolerant to conventional therapy: added benefit not proven
  • who have had an inadequate response to, lost response to, or were intolerant to a biologic therapy (TNF-alpha antagonist or integrin inhibitor or interleukin inhibitor): added benefit not proven
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2023-06-15 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form